Accelerating PK and ADA bioanalytical assay development
Watch now and discover how Gyrolab® streamlines preclinical bioanalytical workflows—reducing development time while improving assay performance.
Preclinical bioanalysis demands precision, speed, and reliability. Traditional methods often fall short when you need to move quickly from development to critical decision-making. This webinar demonstrates how automated immunoassays can transform your approach to pharmacokinetic (PK) and anti-drug antibody (ADA) analysis.
What you'll learn
Join Alejandro Rodriguez, Principal Scientist at Genentech, as he presents two compelling case studies that showcase practical solutions for common bioanalytical challenges:
Case Study 1: Generic ADA Assay Development Learn how to develop a plug-and-play ADA assay for cynomolgus monkey studies. Discover the advantages of wide dynamic range for signal-to-noise reporting and enhanced drug tolerance compared to traditional ELISA methods.
Case Study 2: Optimizing PK Assays Across Sample Types See how different Gyrolab Bioaffy™ microfluidic disc enable seamless transitions from human serum to cerebrospinal fluid (CSF) analysis—optimizing both sensitivity and dynamic range with minimal development time.
Why this matters for your lab
- Faster decisions: Reduce assay development time without compromising data quality
- Improved workflows: Streamline transitions between sample types and study phases
- Enhanced performance: Achieve better drug tolerance and dynamic range than conventional methods
- Practical insights: Learn from real-world applications at a leading biopharmaceutical company
If you have problems viewing the webinar, please contact maritha.lundin@gyrosproteintech.com